Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adverse Events From Long-Term Rituximab Use in MS

Publish date:: April 2, 2019

Key clinical point: During a mean follow-up of 33 months, serious infections while taking rituximab occurred in 8.1% of patients with MS and related disorders.

Major finding: In all, 50 patients (6.5%) experienced an infection that resulted in a hospitalization.

Study details: A retrospective chart review of 769 patients with MS and related disorders.

Disclosures: Ms. Vollmer reported having no financial disclosures. Many of her coauthors reporting having numerous financial ties to the pharmaceutical industry.

Citation:

Vollmer B et al. ACTRIMS Forum 2019, Poster 113

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,